U.S. flag

An official website of the United States government

NM_033118.4(MYLK2):c.260C>T (p.Ala87Val) AND Cardiomyopathy, hypertrophic, midventricular, digenic

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Nov 30, 2001
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000004465.2

Allele description [Variation Report for NM_033118.4(MYLK2):c.260C>T (p.Ala87Val)]

NM_033118.4(MYLK2):c.260C>T (p.Ala87Val)

Gene:
MYLK2:myosin light chain kinase 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
20q11.21
Genomic location:
Preferred name:
NM_033118.4(MYLK2):c.260C>T (p.Ala87Val)
HGVS:
  • NC_000020.11:g.31820333C>T
  • NG_012847.1:g.5959C>T
  • NM_033118.4:c.260C>TMANE SELECT
  • NP_149109.1:p.Ala87Val
  • NP_149109.1:p.Ala87Val
  • LRG_392t1:c.260C>T
  • LRG_392:g.5959C>T
  • LRG_392p1:p.Ala87Val
  • NC_000020.10:g.30408136C>T
  • NM_033118.3:c.260C>T
  • NM_033118.4:c.260C>T
  • Q9H1R3:p.Ala87Val
Protein change:
A87V; ALA87VAL
Links:
UniProtKB: Q9H1R3#VAR_014197; OMIM: 606566.0001; dbSNP: rs121908107
NCBI 1000 Genomes Browser:
rs121908107
Molecular consequence:
  • NM_033118.4:c.260C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cardiomyopathy, hypertrophic, midventricular, digenic
Identifiers:
MedGen: C4016270

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000024638OMIM
no assertion criteria provided
Pathogenic
(Nov 30, 2001)
germlineliterature only

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only

Citations

PubMed

The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation.

Davis JS, Hassanzadeh S, Winitsky S, Lin H, Satorius C, Vemuri R, Aletras AH, Wen H, Epstein ND.

Cell. 2001 Nov 30;107(5):631-41.

PubMed [citation]
PMID:
11733062

Details of each submission

From OMIM, SCV000024638.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (1)

Description

Davis et al. (2001) identified a double point mutation in the MYLK2 gene on the maternal haplotype in a 13-year-old white male proband with early midventricular hypertrophic cardiomyopathy (see 192600). The MYLK2 mutations were ala87 to val (A87V) and ala95 to glu (A95E; 606566.0002). The proband also inherited a glu743-to-asp mutation (E743D; 160760.0024) in the beta-myosin gene (160760) from his father. Although the son had significant disease at an early age, the father and mother came to medical attention only after the diagnosis of the son. Echocardiographic evaluation showed that both parents had similarly abnormal asymmetrically thickened hearts. Although the kindred was too small for linkage analysis, kinetic studies revealed that the mutant MYLK2 had a V(max) almost double that of wildtype MYLK2, which the authors suggested may stimulate cardiac hypertrophy. Davis et al. (2001) concluded that the increased severity of the disease at such a young age in the proband suggests a compound effect.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 28, 2024